Ping Ye Selected Research

Dyslipidemias (Dyslipidemia)

12/2017	Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study.
3/2015	Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China.
11/2014	Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
11/2014	Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
8/2014	Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
10/2011	Influence of low high-density lipoprotein cholesterol on arterial stiffening and left ventricular diastolic dysfunction in essential hypertension.
1/2009	Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
7/2005	Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia.
6/2003	A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ping Ye Research Topics

Disease

26	Inflammation (Inflammations) 04/2024 - 12/2004
20	Neoplasms (Cancer) 01/2024 - 12/2006
17	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 02/2005
14	Hypertension (High Blood Pressure) 01/2022 - 12/2003
14	Infections 09/2019 - 04/2004
12	Heart Failure 05/2023 - 10/2012
12	Cardiomegaly (Heart Hypertrophy) 01/2021 - 12/2003
11	Hypertrophy 01/2021 - 02/2005
10	Fibrosis (Cirrhosis) 01/2024 - 10/2006
10	Myocardial Infarction 01/2018 - 07/2005
9	Dyslipidemias (Dyslipidemia) 12/2017 - 06/2003
8	COVID-19 09/2021 - 01/2020
7	Chronic Hepatitis B 01/2023 - 08/2013
7	Chronic Renal Insufficiency 01/2022 - 01/2013
7	Reperfusion Injury 01/2021 - 01/2007
7	Type 2 Diabetes Mellitus (MODY) 10/2020 - 01/2014
6	Non-alcoholic Fatty Liver Disease 01/2024 - 01/2019
6	Hyperplasia 01/2022 - 06/2014
6	Insulin Resistance 01/2022 - 01/2006
6	Breast Neoplasms (Breast Cancer) 01/2021 - 02/2017
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2017 - 03/2012
6	Coronary Artery Disease (Coronary Atherosclerosis) 12/2015 - 10/2005
5	Rheumatoid Arthritis 01/2023 - 01/2008
5	Coronary Disease (Coronary Heart Disease) 10/2022 - 07/2007
5	Hypercholesterolemia 08/2017 - 10/2006
5	Hypoxia (Hypoxemia) 01/2016 - 06/2007
5	Ischemia 01/2013 - 07/2005
4	Obesity 01/2024 - 06/2005
4	Body Weight (Weight, Body) 05/2023 - 02/2005
4	Atherosclerosis 09/2021 - 11/2012
4	Atrial Fibrillation 01/2021 - 01/2012
4	Essential Hypertension 02/2012 - 10/2006
3	Aortic Aneurysm (Aneurysm, Aortic) 04/2024 - 05/2013
3	Prostatic Neoplasms (Prostate Cancer) 11/2023 - 01/2022
3	Anemia 04/2023 - 01/2020
3	Lupus Nephritis 01/2023 - 01/2020
3	Thoracic Aortic Aneurysm 12/2022 - 01/2018
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2019
3	Pulmonary Hypertension 01/2022 - 01/2017
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2012
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022 - 11/2014
3	Arteriosclerosis 01/2020 - 06/2014
3	Pain (Aches) 01/2020 - 01/2018
3	Carcinogenesis 01/2020 - 04/2011
3	Carotid Artery Diseases 09/2019 - 07/2014
3	Stroke (Strokes) 05/2019 - 07/2007
3	Neointima 01/2019 - 01/2016
3	Diabetes Mellitus 01/2017 - 07/2012

Drug/Important Bio-Agent (IBA)

21	LipidsIBA 01/2024 - 10/2006
13	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2002
13	oxidized low density lipoproteinIBA 05/2022 - 06/2003
12	Angiotensin IIIBA 04/2024 - 02/2005
10	CytokinesIBA 01/2020 - 03/2003
10	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018 - 10/2012
9	Messenger RNA (mRNA)IBA 04/2024 - 02/2005
9	Blood Glucose (Blood Sugar)IBA 05/2023 - 07/2012
9	Glucose (Dextrose)FDA LinkGeneric 05/2023 - 04/2012
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2024 - 10/2005
8	Biomarkers (Surrogate Marker)IBA 11/2023 - 05/2004
8	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 01/2013
8	HomocysteineIBA 01/2021 - 01/2008
8	PPAR gammaIBA 02/2014 - 12/2004
7	LDL CholesterolIBA 01/2022 - 01/2014
7	HDL CholesterolIBA 01/2021 - 10/2011
7	MicroRNAs (MicroRNA)IBA 01/2020 - 07/2011
7	Pioglitazone (Actos)FDA Link 02/2014 - 02/2005
6	xuezhikangIBA 01/2021 - 10/2006
6	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2014
6	Insulin-Like Growth Factor I (IGF-1)IBA 01/2013 - 11/2004
5	LipopolysaccharidesIBA 01/2021 - 05/2012
5	CholesterolIBA 01/2019 - 01/2016
5	Troponin T (Troponin T1)IBA 01/2017 - 01/2012
5	Atorvastatin (Lipitor)FDA Link 12/2015 - 12/2005
5	PPAR alphaIBA 10/2010 - 12/2004
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2024 - 02/2008
4	Antiviral Agents (Antivirals)IBA 01/2023 - 04/2004
4	InflammasomesIBA 12/2022 - 12/2014
4	Dual-Specificity PhosphatasesIBA 01/2021 - 01/2019
4	CreatinineIBA 01/2021 - 11/2010
4	Hepatitis B e AntigensIBA 01/2020 - 01/2014
3	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2024 - 01/2016
3	iguratimodIBA 01/2023 - 01/2020
3	1,3,4,6- tetra- O- acetyl- 2- azido- 2- deoxyglucopyranose (TAAD)IBA 12/2022 - 01/2018
3	Uric Acid (Urate)IBA 11/2021 - 01/2014
3	Serum AlbuminIBA 01/2021 - 12/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2003
3	C-Reactive ProteinIBA 01/2021 - 01/2014
3	EnzymesIBA 01/2020 - 10/2019
3	Indicators and Reagents (Reagents)IBA 01/2020 - 01/2013
3	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 01/2012
3	Rosuvastatin Calcium (Crestor)FDA Link 09/2019 - 11/2012
3	Insulin (Novolin)FDA Link 01/2019 - 06/2007
3	AldosteroneIBA 01/2018 - 10/2007
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2016 - 09/2013
3	HDL LipoproteinsIBA 01/2016 - 10/2011
3	Complementary DNA (cDNA)IBA 01/2015 - 03/2002

Therapy/Procedure

29	Therapeutics 02/2023 - 03/2003
4	Ligation 01/2017 - 02/2005
3	Renal Dialysis (Hemodialysis) 01/2022 - 01/2013
3	Transplantation 01/2020 - 05/2013